EA201790063A1 - Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения - Google Patents

Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения

Info

Publication number
EA201790063A1
EA201790063A1 EA201790063A EA201790063A EA201790063A1 EA 201790063 A1 EA201790063 A1 EA 201790063A1 EA 201790063 A EA201790063 A EA 201790063A EA 201790063 A EA201790063 A EA 201790063A EA 201790063 A1 EA201790063 A1 EA 201790063A1
Authority
EA
Eurasian Patent Office
Prior art keywords
interleukin
methods
application
fusion protein
polypeptide
Prior art date
Application number
EA201790063A
Other languages
English (en)
Other versions
EA035956B1 (ru
Inventor
Томас Малек
Original Assignee
Юниверсити Оф Майами
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836871&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790063(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юниверсити Оф Майами filed Critical Юниверсити Оф Майами
Publication of EA201790063A1 publication Critical patent/EA201790063A1/ru
Publication of EA035956B1 publication Critical patent/EA035956B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

Предусмотрены различные способы и композиции, которые можно использовать для модулирования иммунной системы. Композиции включают в себя слитый белок, содержащий (а) первый полипептид, содержащий интерлейкин-2 (IL-2) или его функциональный вариант или фрагмент; и (b) второй полипептид, слитый в пределах рамки считывания с первым полипептидом, причем второй полипептид содержит внеклеточный домен рецептора интерлейкина-2 альфа (IL-2Rα) или его функциональный вариант или фрагмент, и при этом слитый белок характеризуется активностью IL-2. Предусмотрены различные способы модулирования иммунного ответа у субъекта, предусматривающие введение нуждающемуся в этом субъекту терапевтически эффективного количества раскрытого в настоящем документе слитого белка IL-2/IL-2Rα.
EA201790063A 2014-08-06 2015-08-05 Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения EA035956B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033726P 2014-08-06 2014-08-06
PCT/US2015/043792 WO2016022671A1 (en) 2014-08-06 2015-08-05 Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Publications (2)

Publication Number Publication Date
EA201790063A1 true EA201790063A1 (ru) 2017-06-30
EA035956B1 EA035956B1 (ru) 2020-09-04

Family

ID=53836871

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202091342A EA202091342A3 (ru) 2014-08-06 2015-08-05 Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
EA201790063A EA035956B1 (ru) 2014-08-06 2015-08-05 Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202091342A EA202091342A3 (ru) 2014-08-06 2015-08-05 Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения

Country Status (21)

Country Link
US (2) US20170233448A1 (ru)
EP (1) EP3177307A1 (ru)
JP (3) JP6723982B2 (ru)
KR (1) KR102653758B1 (ru)
CN (2) CN107074967B (ru)
AU (3) AU2015301071C1 (ru)
BR (1) BR112017001940A2 (ru)
CA (1) CA2957273C (ru)
CL (1) CL2017000284A1 (ru)
CO (1) CO2017002166A2 (ru)
EA (2) EA202091342A3 (ru)
IL (2) IL250007B (ru)
MA (2) MA40094B1 (ru)
MX (1) MX2017001062A (ru)
MY (1) MY180831A (ru)
PE (1) PE20170503A1 (ru)
PH (1) PH12017500042A1 (ru)
SA (1) SA517380842B1 (ru)
SG (2) SG10201913695PA (ru)
TN (1) TN2017000020A1 (ru)
WO (1) WO2016022671A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP6306201B2 (ja) 2014-02-06 2018-04-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ インターロイキン−２融合タンパク質及びその使用
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
EP3458485B1 (en) * 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3084262A1 (en) 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3768700A1 (en) * 2018-03-23 2021-01-27 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
CA3094112A1 (en) * 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX2021011258A (es) * 2019-03-18 2021-12-10 Biontech Cell & Gene Therapies Gmbh Variantes de interleucina-2 (il2) y receptor de interleucina-2 (il2r) para la activacion especifica de celulas efectoras inmunitarias.
CN111944036A (zh) 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド ＭＡｄＣＡＭ標的化免疫寛容
CA3136992A1 (en) * 2019-05-24 2020-12-03 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
US20210038684A1 (en) * 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
WO2021055568A1 (en) * 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
WO2021074689A1 (en) * 2019-10-18 2021-04-22 Alkermes Pharma Ireland Limited Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors
JP2023510115A (ja) 2019-12-20 2023-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規ｉｌ２アゴニストおよびそれらの使用方法
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11597753B2 (en) 2020-04-30 2023-03-07 Immune Targeting, Inc. Activatable IL2 composition and methods of use
WO2023154894A2 (en) * 2022-02-11 2023-08-17 Alkermes Pharma Ireland Limited Compositions and methods for cancer immunotherapy
WO2023159135A2 (en) * 2022-02-16 2023-08-24 University Of Miami Il-2 and tl1a fusion proteins and methods of use thereof
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2209172C (en) * 1994-12-28 2007-04-10 University Of Kentucky Murine monoclonal anti-idiotype antibody 3h1
DE19701141C1 (de) * 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
WO2003029475A1 (en) * 2001-09-28 2003-04-10 Dnavec Research Inc. MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF
PL1899364T3 (pl) * 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
CN101255197B (zh) * 2008-03-28 2012-01-25 浙江海正药业股份有限公司 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
WO2011123683A2 (en) * 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
US20230079120A1 (en) 2023-03-16
JP2023099045A (ja) 2023-07-11
JP2021000084A (ja) 2021-01-07
CO2017002166A2 (es) 2017-05-19
CN113912737A (zh) 2022-01-11
TN2017000020A1 (en) 2018-07-04
CN107074967A (zh) 2017-08-18
PE20170503A1 (es) 2017-05-11
SA517380842B1 (ar) 2021-12-26
PH12017500042A1 (en) 2017-05-22
JP6723982B2 (ja) 2020-07-15
WO2016022671A1 (en) 2016-02-11
MA40094A1 (fr) 2021-09-30
CL2017000284A1 (es) 2017-11-17
JP7272663B2 (ja) 2023-05-12
AU2022204034A1 (en) 2022-07-14
SG10201913695PA (en) 2020-03-30
AU2020203352B2 (en) 2022-03-10
US20170233448A1 (en) 2017-08-17
AU2015301071C1 (en) 2020-07-02
CA2957273C (en) 2023-03-14
CA2957273A1 (en) 2016-02-11
MA40721A (fr) 2017-06-13
MY180831A (en) 2020-12-10
IL250007A0 (en) 2017-03-30
SG11201700706WA (en) 2017-02-27
IL250007B (en) 2020-07-30
BR112017001940A2 (pt) 2017-11-28
KR20170030646A (ko) 2017-03-17
JP2017523789A (ja) 2017-08-24
KR102653758B1 (ko) 2024-04-04
AU2015301071B2 (en) 2020-03-05
EA202091342A2 (ru) 2020-11-30
MA40094B1 (fr) 2022-05-31
AU2015301071A1 (en) 2017-02-02
EA035956B1 (ru) 2020-09-04
AU2020203352A1 (en) 2020-07-02
IL275944A (en) 2020-08-31
MX2017001062A (es) 2017-07-14
EP3177307A1 (en) 2017-06-14
IL275944B (en) 2022-02-01
EA202091342A3 (ru) 2020-12-30
CN107074967B (zh) 2021-06-08

Similar Documents

Publication Publication Date Title
EA201790063A1 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
DOP2017000258A (es) Proteínas de fusión
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EA201990017A1 (ru) Антитела к миостатину и способы их применения
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
BR112018011073A2 (pt) anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX2016008782A (es) Variantes de region fc con union mejorada de la proteina a.
TR201909342T4 (tr) Rekombi̇nant marek hastaliği vi̇rüsleri̇ ve bunlarin kullanimlari
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
EA201690826A1 (ru) Рекомбинантные гликопротеиды и их применения
MX2015011931A (es) Expresion mejorada de proteinas de picornavirus.
MX2018013177A (es) Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas.
EA202092327A1 (ru) Варианты lfa3 и их композиции и применение
EA201991340A1 (ru) Способы индуцирования иммунологической толерантности к факторам свертывания крови
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
AR099080A1 (es) Variantes de región fc con propiedades de unión a fcrn (receptor fc neonatal) modificadas y de unión a proteína a mantenidas
EA201992746A3 (ru) Рекомбинантные гликопротеиды и их применения
TH1501005499A (th) โพลีเปปไทด์ IL-22 และฟิวชันโปรตีน IL-22 Fc และวิธีการใช้

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM